Immunogenicity comparison of a multi-antigenic peptide bearing v3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice

Journal of Peptide Science

Volumn 6, Issue 5, 2000, Pages 217-224

  Cruz, Luis J ^a   Quintana, Diogenes ^a   Iglesias, Enrique ^a   Garcia, Yairet ^a   Huerta, Vivian ^a   Garay, Hilda E ^a   Duarte, Carlos ^a   Reyes, Osvaldo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Boc chemistry; HIV 1; Multiple antigen peptide; Synthetic peptides; V3 loop

Indexed keywords

ANTIBODY; GLYCOPROTEIN GP 120; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; COVALENT BOND; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

AMINO ACIDS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EPITOPES, B-LYMPHOCYTE; FEMALE; FORMIC ACID ESTERS; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; MICE; MICE, INBRED BALB C; PEPTIDES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034019195     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1387(200005)6:5<217::AID-PSC242>3.0.CO;2-U     Document Type: Article

References (29)

1. Schutze MP, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier induced epitopic suppression a major issue for the future synthetic vaccines. J. Immunol. 1985; 135: 2319-2322.
2. Liu F-T, Zinnecker M, Hamaoka T, Katz DH. New procedures for preparation and isolation of conjugates of proteins and synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates. Biochemistry 1979; 18: 690-697.
3. Tam JP. Synthetic peptide vaccine design: synthetic and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. 1988; 86: 5409-5413.
4. Tam JP. High-density multiple antigen-peptide system for preparation of antipeptide antibodies. Methods Enzymol. 1989; 168: 7-15.
5. Tam JP, Lu YA. Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes. Proc. Natl. Acad. Sci. 1989; 86: 9084-9088.
6. Tam JP, Clavijo P, Lu YA, Nussenzweig V, Zavala P. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 1990; 171: 299-306.
7. Wang R, Charoenvit Y, Corradin G, Porrozzi R, Hunter RL, Glenn G, Alving CR, Church P, Hoffman SL. Induction of protective polyclonal antibodies by immunization with a Plasmodiumyoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 1995; 154: 2784-2793.
8. Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, Berzofsky JA. Candidate HIV type 1 multi-determinant cluster peptide-P18MN vaccine constructs elicit type 1 helper T-cells, cytotoxic T-cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res. Human Retroviruses 1996; 12: 259-272.
9. Francis MJ, Hastings GZ, Brown F, McDermed J, Lu YA, Tam JP. Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus. Immunology 1991; 73: 249-254.
10. 22 virus strain. Vaccine 1996; 14: 1375-1380.
11. Duarte CA, Montero M, Seralena A, Valdés R, Jiménez V, Benítez J, Narciandi E, Madrazo J, Padrón G, Sánchez G, Gjilliam G, Pearson C, Domínguez MC, Wharen B, Menéndez A. Multiepitope polypeptide of the HIV-1 envelope induces monoclonal antibodies against V3 loop. AIDS Res. Human Retroviruses 1994; 10: 235-243.
12. Montero M, Menéndez A, Domínguez MC, Navea L, Vilarubia OL, Quintana D, Izquierdo M, Jiménez V, Reyes O, Lobaina L, Noa E, Duarte CA. Broadly reactive antibodies against a gp120 V3-loop Multi-Epitope Polypeptide neutralize different isolates of Human Immunodeficiency Virus type 1 (HIV-1). Vaccine 1997; 15: 1200-1208.
13. Javaherian K, Langlois AJ, McDanal C, Ross K, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. 1989; 86: 6768-6772.
14. Moore J, Nara P. The role of the V3 of gp120 in HIV infection. AIDS 1991; 5: 521-533.
15. Houghten RA, Graw ST, Bray MK. Simultaneous multiple peptide synthesis: the rapid preparation of large numbers of discrete peptides for biological, immunological and methodological studies. BioTechniques 1996; 4: 522-526.
16. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in solid-phase synthesis of peptides. Anal. Biochem. 1970; 34: 595-598.
17. Beales D, Finch R, McLean AE, Smith M, Wilson ID. Determination of penicillamine and other thiols by combined high-performance liquid chromatography and post-column reaction with Ellman's reagent: application to human urine. J. Chromotogr. 1981; 226: 498-503.
18. Yourno J, Josephs SF, Reitz M, Zagury D, Wong-Staal F, Gallo RC. Nucleotide sequences analysis of the env gene of a new Zairian isolate of HIV-1. AIDS Res. Human Retroviruses 1988; 4: 165-173.
19. Panina-Bordingnon P, Tan G, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T-cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T-cells. Eur. J. Immunol. 1989; 19: 2237-2247.
20. Borras-Cuest F, Fedon Y, Pellit-Camordan A. Enhancement of peptide immunogenicity by linear polymerization. Eur. J. Immunol. 1988; 18: 199-202.
21. Silva RR, Sosa MSH, Nieto GG, Martinez LSH, Mas JRF, Pérez LIN, Inés L, Morales JG, Morera V, González S, Santos B, Menéndez E, Acosta A, Couzeau E, Cruz S, Musacchlo A. Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and its use in vaccine preparations. European Patent Application, EP 0474 313 A2, Erhard-strasse 27, D-8000, München 2, Germany, 1992.
22. Gomez CE, Lopez-Campistrous AE, Duarte CA. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera. J. Virol. Methods 1998; 71: 7-16.
23. Romero PJ, Tam JP, Schlesinger D, Clavijo P, Gibson H, Barr PJ, Nussenzweig RS, Zavala F. Multiple T-helper cell epitopes of the circumsporozoite protein of Plasmodium berghei. Eur. J. Immunol. 1988; 18: 1951-1957.
24. Nardelli B, Lu YA, Shiu DR, Delpierre-Defoort C, Profy AT, Tam JP. A chemically defined synthetic vaccine model for HIV-1. J. Immunol. 1992; 148: 914-920.
25. Chai SK, Clavijo P, Tam JP, Zavala F. Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J. Immunol. 1992; 149: 2385-2390.
26. Kelder HC, Schlesinger D, Valentine FT. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple-chain peptides. J. Immunol. 1994; 152: 4139-4148.
27. Wang CY, Looney DJ, Li ML, Walfield AM, Ye J, Hosen B, Tam JP, Wong-Staal F. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991; 254: 285-288.
28. Collins WE, Sullivan JS, Morris CL, Galland GG, Jue DL, Fang S, Wohlhueter R, Reed RC, Yang C, Hunter RL, Lal AA. Protective immunity induced in squirrel monkeys with a multiple-antigen construct against the circumsporozoite protein of Plasmodium vivax. Am. J. Trop. Med. Hyg. 1997; 56: 200-210.
29. Li JKK, Yang YY. Mapping of two immunodominant antigenic epitopes conserved among the major inner capsid protein, VP7 of five blue-tongue viruses. Virology 1990; 178: 552-559.